SARS-CoV-2 mRNA vaccine

BIOLOGICAL3 trials

Sponsors

NYU Langone Health, Walvax Biotechnology Co., Ltd., TruDiagnostic

Conditions

COVID-19Covid19Multiple SclerosisSARS-CoV-2

Phase 3

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

Walvax Biotechnology Co., Ltd.COVID-19, SARS-CoV-2

Start: 2021-07-22End: 2023-05-30Target: 28000Updated: 2021-11-18

Unknown Phase

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

CompletedNCT04843774

NYU Langone HealthMultiple Sclerosis

Start: 2021-04-20End: 2023-04-18Updated: 2023-11-08

Methylation Effects of COV-19 Infection and Vaccinations

TruDiagnosticCovid19

Start: 2021-03-10End: 2022-03-10Target: 60Updated: 2021-06-30

Related Papers

Neutralization of ARCoV-induced sera against SARS-CoV-2 variants

Human Vaccines & Immunotherapeutics2022-07-114 citations

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

2022-01-2458 citations